258 related articles for article (PubMed ID: 22176145)
1. Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy.
Üçeyler N; He L; Schönfeld D; Kahn AK; Reiners K; Hilz MJ; Breunig F; Sommer C
J Peripher Nerv Syst; 2011 Dec; 16(4):304-14. PubMed ID: 22176145
[TBL] [Abstract][Full Text] [Related]
2. Functional and structural nerve fiber findings in heterozygote patients with Fabry disease.
Torvin Møller A; Winther Bach F; Feldt-Rasmussen U; Rasmussen A; Hasholt L; Lan H; Sommer C; Kølvraa S; Ballegaard M; Staehelin Jensen T
Pain; 2009 Sep; 145(1-2):237-45. PubMed ID: 19665302
[TBL] [Abstract][Full Text] [Related]
3. Enzyme replacement therapy and intraepidermal innervation density in Fabry disease.
Schiffmann R; Hauer P; Freeman B; Ries M; Scott LJ; Polydefkis M; Brady RO; McArthur JC; Wagner K
Muscle Nerve; 2006 Jul; 34(1):53-6. PubMed ID: 16583374
[TBL] [Abstract][Full Text] [Related]
4. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease.
Schiffmann R; Floeter MK; Dambrosia JM; Gupta S; Moore DF; Sharabi Y; Khurana RK; Brady RO
Muscle Nerve; 2003 Dec; 28(6):703-10. PubMed ID: 14639584
[TBL] [Abstract][Full Text] [Related]
5. Neuropathic symptoms and findings in women with Fabry disease.
Laaksonen SM; Röyttä M; Jääskeläinen SK; Kantola I; Penttinen M; Falck B
Clin Neurophysiol; 2008 Jun; 119(6):1365-72. PubMed ID: 18387337
[TBL] [Abstract][Full Text] [Related]
6. Neuropathy and Fabry disease: pathogenesis and enzyme replacement therapy.
Schiffmann R
Acta Neurol Belg; 2006 Jun; 106(2):61-5. PubMed ID: 16898255
[TBL] [Abstract][Full Text] [Related]
7. Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy.
Bersano A; Lanfranconi S; Valcarenghi C; Bresolin N; Micieli G; Baron P
Acta Neurol Scand; 2012 Aug; 126(2):77-97. PubMed ID: 22428782
[TBL] [Abstract][Full Text] [Related]
8. Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy.
Hilz MJ; Brys M; Marthol H; Stemper B; Dütsch M
Neurology; 2004 Apr; 62(7):1066-72. PubMed ID: 15079003
[TBL] [Abstract][Full Text] [Related]
9. Dialysis and transplantation in Fabry disease: indications for enzyme replacement therapy.
Mignani R; Feriozzi S; Schaefer RM; Breunig F; Oliveira JP; Ruggenenti P; Sunder-Plassmann G
Clin J Am Soc Nephrol; 2010 Feb; 5(2):379-85. PubMed ID: 20056752
[TBL] [Abstract][Full Text] [Related]
10. The relation between small nerve fibre function, age, disease severity and pain in Fabry disease.
Biegstraaten M; Binder A; Maag R; Hollak CE; Baron R; van Schaik IN
Eur J Pain; 2011 Sep; 15(8):822-9. PubMed ID: 21334933
[TBL] [Abstract][Full Text] [Related]
11. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry.
Ortiz A; Cianciaruso B; Cizmarik M; Germain DP; Mignani R; Oliveira JP; Villalobos J; Vujkovac B; Waldek S; Wanner C; Warnock DG
Nephrol Dial Transplant; 2010 Mar; 25(3):769-75. PubMed ID: 19846394
[TBL] [Abstract][Full Text] [Related]
12. Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy.
Breunig F; Wanner C
J Nephrol; 2008; 21(1):32-7. PubMed ID: 18264934
[TBL] [Abstract][Full Text] [Related]
13. Small fiber neuropathy in female patients with fabry disease.
Liguori R; Di Stasi V; Bugiardini E; Mignani R; Burlina A; Borsini W; Baruzzi A; Montagna P; Donadio V
Muscle Nerve; 2010 Mar; 41(3):409-12. PubMed ID: 20120004
[TBL] [Abstract][Full Text] [Related]
14. Enzyme replacement therapy in severe Fabry disease with renal failure: a 1-year follow-up.
Tsambaos D; Chroni E; Manolis A; Monastirli A; Pasmatzi E; Sakkis T; Davlouros P; Goumenos D; Katrivanou A; Georgiou S
Acta Derm Venereol; 2004; 84(5):389-92. PubMed ID: 15370707
[TBL] [Abstract][Full Text] [Related]
15. Cystatin C as a marker of early changes of renal function in Fabry nephropathy.
Feriozzi S; Germain DP; Di Vito R; Legrand A; Ricci R; Barbey F
J Nephrol; 2007; 20(4):437-43. PubMed ID: 17879210
[TBL] [Abstract][Full Text] [Related]
16. Impaired small fiber conduction in patients with Fabry disease: a neurophysiological case-control study.
Üçeyler N; Kahn AK; Kramer D; Zeller D; Casanova-Molla J; Wanner C; Weidemann F; Katsarava Z; Sommer C
BMC Neurol; 2013 May; 13():47. PubMed ID: 23705943
[TBL] [Abstract][Full Text] [Related]
17. Fabry disease: clinical spectrum and evidence-based enzyme replacement therapy.
Desnick RJ; Banikazemi M
Nephrol Ther; 2006 Jan; 2 Suppl 2():S172-85. PubMed ID: 17373219
[TBL] [Abstract][Full Text] [Related]
18. Neurological complications in Fabry disease.
Dütsch M; Hilz MJ
Rev Med Interne; 2010 Dec; 31 Suppl 2():S243-50. PubMed ID: 21211673
[TBL] [Abstract][Full Text] [Related]
19. Sensory changes and loss of intraepidermal nerve fibers in painful unilateral nerve injury.
Schüning J; Scherens A; Haussleiter IS; Schwenkreis P; Krumova EK; Richter H; Maier C
Clin J Pain; 2009 Oct; 25(8):683-90. PubMed ID: 19920717
[TBL] [Abstract][Full Text] [Related]
20. Enzyme replacement therapy stabilized white matter lesion progression in Fabry disease.
Fellgiebel A; Gartenschläger M; Wildberger K; Scheurich A; Desnick RJ; Sims K
Cerebrovasc Dis; 2014; 38(6):448-56. PubMed ID: 25502511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
